바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.75 No.1
Citation Share

Mycobacterium intracellulare Pulmonary Disease with Endobronchial Caseation in a Patient Treated with Methotrexate

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2013, v.75 no.1, pp.28-31
Jin Sun Park (Gachon University)
Eul Sik Jung (Gil Hospital)
Woosuk Choi (Gachon University Medicine and Science)
Soo Yong Park (Gachon University Medicine and Science)
Min Young Rim (Gachon University of Medicine and Science)
Inku Yu (Gachon University Medicine and Science)
Hyeonsu Park (Gachon University Medicine and Science)





Jin, S. P. , Eul, S. J. , Woosuk, C. , Soo, Y. P. , Min, Y. R. , Inku, Y. , Hyeonsu, P. , & (2013). Mycobacterium intracellulare Pulmonary Disease with Endobronchial Caseation in a Patient Treated with Methotrexate. Tuberculosis & Respiratory Diseases, 75(1), 28-31.
  • Downloaded
  • Viewed
PDF Download

Abstract

Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.

keywords
Nontuberculous Mycobacteria, Tuberculosis, Pulmonary, Methotrexate, Arthiritis, Rheumatoid, Bronchial Diseaseseffectiveness

Reference

1.

Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74.

2.

Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S179-85.

3.

Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-8.

4.

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.

5.

Shih JY, Wang HC, Chiang IP, Yang PC, Luh KT. Endobronchial lesions in a non-AIDS patient with disseminated Mycobacterium avium-intracellulare infection. Eur Respir J 1997;10:497-9.

6.

Mehle ME, Adamo JP, Mehta AC, Wiedemann HP, Keys T, Longworth DL. Endobronchial Mycobacterium avium-intracellulare infection in a patient with AIDS. Chest 1989;96:199- 201.

7.

Lee JH, Son KS, Park JH, Kim JC, Lee HW, Kim CH. Mycobacterium avium infection presenting as endobronchial lesions in an immunocompetent patient. Tuberc Respir Dis 2006;60:571-5.

8.

O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States: results from a national survey. Am Rev Respir Dis 1987;135:1007-14.

9.

Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev 2005;203:38- 47.

10.

Kolokotronis A, Avramidou E, Zaraboukas T, Mandraveli K, Alexiou S, Antoniades D. Oral tuberculosis associated with a treatment with anti-rheumatic drugs. J Oral Pathol Med 2006;35:123-5.

11.

Lee JY, Yi CA, Kim TS, Kim H, Kim J, Han J, et al. CT scan features as predictors of patient outcome after bronchial intervention in endobronchial TB. Chest 2010;138:380-5.

12.

Watanabe Y, Murakami S, Iwa T. Bronchial stricture due to endobronchial tuberculosis. Thorac Cardiovasc Surg 1988;36:27-32.

13.

Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006;16:282-8.

14.

Luis M, Pacheco-Tena C, Cazarin-Barrientos J, Lino-Perez L, Goycochea MV, Vazquez-Mellado J, et al. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Arthritis Rheum 1999;42:2160-5.

15.

Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy